Hans-Peter Kiem MD

PubMed

• A rescue fanconi anemia humanized mouse model with endogenous FA mutation and high human hematopoietic stem cell chimerism.
  Seunga Choo, Alvin H Tong, Emily Fields, Heather M Mack, Olivier Humbert
  Molecular Therapy. Methods & Clinical Development. 2025-09-11
• Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence.
  Lucy H Maynard, Eric J Cavanaugh, Haiying Zhu, Carly E Starke, Sarah M Doherty
  Blood. 2025-08-14
• Engraftment and persistence ofbase-edited hematopoietic stem cells in nonhuman primates.
  Stefan Radtke, Emily Fields, Kyle Swing, Greta Kanestrom, Jonathan S Yen
  Science Translational Medicine. 2025-08-13

Abstracts/Posters

• Fully Closed, Large-Scale, and Clinical Grade Cell Sorting of Hematopoietic Stem Cell (HSC)-Enriched CD90+ Cells for Transplantation and Gene Therapy
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
  Hans-Peter Kiem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Non-Genotoxic Conditioning Efficiently Depletes Host Hematopoietic Stem Cells and Facilitates Robust Multi-Lineage Engraftment in a Mouse Model of Fanconi Anemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi AnemiaClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all